pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN
Regeneron UK
Regeneron UK Limited
NovaPharmaNews editorial coverage mentioning Regeneron UK — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Tarrytown, USA
- Employees
- 16,715
- Programs
- 5
- Drugs
- 69
- Patents
- 48
News & analysis
NovaPharmaNews articles mentioning Regeneron UK — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Regeneron UK — regulatory, clinical, and market analysis.
Regeneron gene therapy hearing loss pivot
Sensorion has redirected its hearing-loss strategy after Regeneron’s Otarmeni became the first and only FDA-approved in vivo gene therapy for OTOF-related hearing loss. The move underscores a widening split between rare OTOF programs and broader GJB2-targeted opportunities.
When was Dupixent approved for COPD?
The FDA has approved Dupixent as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. The decision gives Regeneron and Sanofi a new regulatory catalyst to track for commercial and investor implications.
Regeneron Pharma Stock Holds Steady Amid EMA Eye Drug Review and Analyst Target Adjustment
Regeneron Pharmaceuticals' stock shows resilience despite a recent analyst price target reduction and ongoing European Medicines Agency (EMA) review of an eye drug. The market appears to be absorbing these developments without significant share price volatility.
Parabilis IPO Plans Following Regeneron Deal: What You Need to Know
Parabilis has announced its IPO plans just a day after the Regeneron deal, signaling a surge in listings. This article explores the implications for the pharmaceutical landscape.
Regeneron Pharma Stock Surges: Fresh Institutional Buying Insights
Regeneron Pharma stock is in the spotlight following significant institutional buying. This article explores the implications for investors and pharma teams.
Regeneron Secures $125M Parabilis Deal for Drug Targets
Regeneron has entered a significant $125M deal with Parabilis to target elusive drug targets. This partnership could reshape competitive dynamics in the pharmaceutical industry.
Regeneron's Phase 3 Skin Cancer Miss: Implications for LAG-3 Development
Regeneron's recent Phase 3 trial failure in skin cancer highlights ongoing challenges in LAG-3 research. This article examines the implications for the pharmaceutical industry.
Regeneron Immunotherapy Combo Fails in Melanoma Trial
Regeneron's recent melanoma trial results raise questions about the future of its immunotherapy combo. Analysts must assess the competitive landscape and investment implications.